All 1 tracked stories fall under one category: market-trends. Parallel (Surterra Holdings, Inc.) is most often covered alongside Nasdaq, which appears in 1 of these 1 story. Their average consequence score of 6 sits level with the 6 recorded across the beat in that window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Parallel (Surterra Holdings, Inc.)
All 1 tracked stories fall under one category: market-trends. Parallel (Surterra Holdings, Inc.) is most often covered alongside Nasdaq, which appears in 1 of these 1 story. Their average consequence score of 6 sits level with the 6 recorded across the beat in that window. Each story carries 2 original sources on average, compared with 2.2 for the broader beat in this window. We currently track 1 Healthcare story that mention Parallel (Surterra Holdings, Inc.), all published on July 27, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Parallel (Surterra Holdings, Inc.). Shared-story counts are live from our verified record — not editorial picks.
SNDL’s completion of the Parallel asset acquisition gives it indirect control of medical cannabis operations in three states, positioning the company to directly expand patient access and standardize products once Nasdaq consolidation is achieved.
Parallel (Surterra Holdings, Inc.) is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.